New study shows that cancer damages its own DNA by pushing key genes to work too hard. Researchers found that the most ...

Boundless Bio (NASDAQ:BOLD) said it has received clearance from the Food and Drug Administration for its investigational new ...

Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...

BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026Portfolio prioritization, including ...

A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...

In a groundbreaking advancement for cancer treatment, a research team led by Professor Xiang David Li from the Department of Chemistry at The University of Hong Kong (HKU) has made significant strides ...

An international team of scientists has analyzed the ongoing colonization by two retroviruses of the germline of koalas and ...

Pancreatic ductal adenocarcinoma (PDAC) is both the most common and the deadliest type of pancreatic cancer. Most treatment ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

An antisense oligonucleotide has been shown to "collapse the entire oncogenic circuit" in pancreatic cancer, triggering ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the disease. Potential treatments typically target a key mutated oncogene called ...